Core Insights - Chemomab Therapeutics Ltd. released results from the Open Label Extension (OLE) of the Phase 2 Spring trial for nebokitug in primary sclerosing cholangitis (PSC) patients, showing high patient retention and positive safety profile [1][2][3] Group 1: Trial Results - Over 90% of eligible Spring trial patients opted to continue into the OLE study [1] - Nebokitug was found to be safe and well-tolerated at doses of 10 mg/kg and 20 mg/kg administered every three weeks for up to 48 weeks [1] - Positive effects included improvements in key liver biomarkers such as the ELF score and the fibrosis biomarker PRO-C3 [2] Group 2: Clinical Outcomes - Liver stiffness scores in nebokitug-treated patients with moderate/advanced disease were significantly lower compared to historical controls [3] - Cholestasis-related markers remained stable over the 48-week treatment period, with total serum bile acids reduced [3] - Clinical events in OLE patients with moderate/advanced disease treated for 48 weeks were significantly lower at 4.8% compared to 25.8% in historical controls [3] Group 3: Placebo Group Results - Results from patients who received a placebo during the double-blind period and then transitioned to 33 weeks of treatment in the OLE were consistent with nebokitug-treated patients, showing stabilization of ELF scores and improvements in liver stiffness [4] Group 4: Market Reaction - Following the announcement, Chemomab stock increased by 2.59%, reaching $1.19 [4]
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease